Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP3 | O14638 | 5/20 | 0.48 |
| ▸ | ENPP1 | P22413 | 4/20 | 0.47 |
| ▸ | ESR1 | P03372 | 12/20 | 0.46 |
| ▸ | STS | P08842 | 2/20 | 0.46 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.46 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.46 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 10/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5417454 | 0.93 | ENPP3 (0.48) | ENPP3ENPP1ESR1STSPSMB1 | |
| SCHEMBL5428177 | 0.92 | ENPP3 (0.48) | ENPP3ENPP1ESR1STSPSMB1 | |
| SCHEMBL5415604 | 0.90 | ENPP3 (0.46) | ENPP3ENPP1ESR1STSPSMB1 | |
| SCHEMBL1358191 | 0.87 | ENPP3 (0.53) | ENPP3ENPP1ESR1STSPSMB1 | |
| SCHEMBL5422570 | 0.87 | ENPP3 (0.51) | ENPP3ENPP1ESR1STSPSMB1 | |
| SCHEMBL6203386 | 0.84 | CHEK2 (0.39) | ENPP3ENPP1ESR1 | |
| SCHEMBL14409262 | 0.83 | ESR1 (0.53) | ESR1PSMB1PSMB5PSMB2ESR2 | |
| SCHEMBL1358938 | 0.83 | ENPP3 (0.47) | ENPP3ENPP1ESR1STSPSMB1 | |
| SCHEMBL1360038 | 0.83 | ENPP3 (0.50) | ENPP3ENPP1ESR1STSPSMB1 | |
| SCHEMBL1359436 | 0.83 | ESR1 (0.56) | ESR1PSMB1PSMB5PSMB2ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7271264-B2 | Pentacyclic oxepines and derivatives thereof, compositions and methods | ELI LILLY AND COMPANY (US) | 2007-09-18 | — | — | US | disclosed |
| US-7271264-B2 | Pentacyclic oxepines and derivatives thereof, compositions and methods | ELI LILLY AND COMPANY (US) | 2007-09-18 | — | — | US | disclosed |
| US-7271264-B2 | Pentacyclic oxepines and derivatives thereof, compositions and methods | ELI LILLY AND COMPANY (US) | 2007-09-18 | — | — | US | disclosed |
| EP-1551822-B1 | PENTACYCLIC OXEPINES AND DERIVATIVES THEREOF, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | LILLY CO ELI (US) | 2006-12-20 | — | — | EP | disclosed |
| US-20050261277-A1 | Pentacyclic oxepines and derivatives thereof, compositions and methods | ELI LILLY AND COMPANY | 2005-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261277-A1 | Pentacyclic oxepines and derivatives thereof, compositions and methods | NR5A1, NR3C2, OXER1 | ENPP3 1667/4885ENPP1 1821/4885ESR1 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.